NR IV therapy delivers nicotinamide riboside, a precursor to NAD⁺, directly into the bloodstream under medical supervision. Inside the body, NR is converted into NAD⁺ through natural cellular pathways that support energy metabolism and mitochondrial function.

NR is a precursor, not NAD⁺ itself. Instead of delivering the active coenzyme directly, NR allows cells to produce NAD⁺ internally. This often results in shorter infusion times and improved tolerability compared to traditional NAD⁺ IV therapy.

NR supports the body’s natural production of NAD⁺ inside cells. While NR does not deliver NAD⁺ directly, it is converted into NAD⁺ through established metabolic pathways.

IV administration: • Bypasses digestion and absorption variability • Allows for predictable, clinician-directed dosing • Provides faster systemic availability • Is delivered under medical supervision Oral NR can still be effective, but IV therapy offers greater control and consistency.

NR IV infusions are typically completed more quickly than NAD⁺ IV infusions. Exact duration depends on dose and individual tolerance, but sessions are generally designed to be efficient and comfortable.

NR IV therapy is generally well tolerated. Many individuals find it more comfortable than NAD⁺ IV therapy, with fewer infusion-related sensations such as chest pressure or nausea.

NR IV therapy is administered as its own controlled infusion. When clinically appropriate, it may be offered as part of a sequential IV protocol, but it is not mixed into the same IV bag with other compounds unless medically indicated.

Frequency varies based on individual goals, health status, and provider assessment. Your clinician will recommend an appropriate schedule based on your response and overall plan of care.

NR IV therapy may be considered by individuals seeking: • Support for cellular energy and metabolism • Mitochondrial support • NAD⁺ pathway optimization • A shorter, well-tolerated NAD-focused IV option A clinical assessment is required to determine appropriateness.